Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen added to background inclisiran in ASCVD patients with elevated LDL-C and lipoprotein(a)
2024-516356-18-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease comparing Pelacarsen + background inclisiran with Placebo + background inclisiran (2 arms). Primary endpoint: Change in log-transformed lipoprotein(a) concentration from baseline at Month 6. Started Feb 2026; status: completed.
02
Drugs
pelacarsen
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on 2024-516356-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516356-18-00.